Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CELGENE CORPORATION via CELGENE CORPORATION
2019 · third_quarter · Q3
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Prescription Drug Pricing Reduction Act of 2019
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. S. 2543, Prescription Drug Pricing Reduction Act of 2019, provisions regarding Medicare Part D / Part B. S. 2546, Safe Step Act, provisions regarding Step Therapy / Fail First. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Restoring the Patient's Voice Act of 2017
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Restoring the Patient's Voice Act of 2017
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Restoring the Patient's Voice Act of 2017
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
Restoring the Patient's Voice Act of 2017
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Protecting Seniors Access to Medicare Act
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
Restoring the Patient's Voice Act of 2017
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
Restoring the Patient's Voice Act of 2017
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.
Restoring the Patient's Voice Act of 2017
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
Protecting Seniors Access to Medicare Act
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
Protecting Seniors Access to Medicare Act
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.
Protecting Seniors Access to Medicare Act
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.
- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.
- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
2019 · second_quarter · Q2
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2019 · first_quarter · Q1
HR 985, FAST Generics Act, provisions regarding REMS. H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2018 · fourth_quarter · Q4
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2018 · third_quarter · Q3
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2018 · second_quarter · Q2
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2018 · first_quarter · Q1
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to regulation of Non-Biological Complex Drugs. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2017 · fourth_quarter · Q4
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2017 · third_quarter · Q3
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs. Issues relating to cancer drug coverage parity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2017 · second_quarter · Q2
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S.974, "CREATES Act of 2017", provisions regarding REMS. H.R. 849, "Protecting Seniors' Access to Medicare Act of 2017", regarding IPAB. Issues relating to Medicare Part D / Part B and the Affordable Care Act. Regulation of Non-Biological Complex Drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2017 · first_quarter · Q1
- Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First. - Issues related to HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. - Issues related to HR 2739/S 1566, "Cancer Drug Coverage Parity Act". - Issues related to HR 1600, "Patients Access To Treatments Act". - Issues related to S 3056, "CREATES Act of 2016", regarding REMS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2016 · fourth_quarter · Q4
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Corporate Tax Reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
CELGENE CORPORATION via CELGENE CORPORATION
2016 · second_quarter · 2A
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
CELGENE CORPORATION via CELGENE CORPORATION
2016 · third_quarter · 3A
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Corporate Tax Reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
CELGENE CORPORATION via CELGENE CORPORATION
2016 · third_quarter · Q3
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
CELGENE CORPORATION via CELGENE CORPORATION
2016 · second_quarter · Q2
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Corporate Tax Reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
CELGENE CORPORATION via CELGENE CORPORATION
2016 · first_quarter · Q1
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Corporate Tax Reform.
CELGENE CORPORATION via CELGENE CORPORATION
2015 · second_quarter · 2A
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2015 · fourth_quarter · Q4
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Corporate Tax Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2015 · third_quarter · 3A
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2015 · second_quarter · Q2
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2015 · first_quarter · Q1
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)
H.R. 1600 (Patient Access to Treaments Act); oral parity; exclusivity incentives for dormant therapies; proposed changes to FDA-authorized risk evaluation and mitigation strategies
general issues related to patient access
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · fourth_quarter · Q4
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
coding related to wound care products; proposed changes to REMS (H.R. 5657)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · third_quarter · Q3
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Corporate Tax Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Corporate Tax Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE